Literature DB >> 8728309

Role of cholesterol in regulating apolipoprotein B secretion by the liver.

G R Thompson1, R P Naoumova, G F Watts.   

Abstract

The review examines the evidence that the supply of cholesterol available for incorporation into nascent lipoprotein particles exerts a regulatory influence on apolipoprotein (apo) B secretion by the liver. Support for this hypothesis comes both from in vitro experiments and from recent observations in normal subjects and patients with dyslipidemia associated with familial hypercholesterolemia, obesity, noninsulin dependent diabetes mellitus, growth hormone deficiency and cholesteryl ester storage disease. The findings do not negate a role for triglyceride synthesis in determining apoB secretion in very low density lipoprotein, but the inhibitory effects on the latter process of pharmacological blockade of cholesterol synthesis or esterification suggest that it is conditional upon an adequate supply of cholesteryl ester.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8728309

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  28 in total

1.  Influence of simvastatin on apoB-100 secretion in non-obese subjects with mild hypercholesterolemia.

Authors:  Heiner K Berthold; Jessica Mertens; Julia Birnbaum; Susanne Brämswig; Thomas Sudhop; P Hugh R Barrett; Klaus von Bergmann; Ioanna Gouni-Berthold
Journal:  Lipids       Date:  2010-05-12       Impact factor: 1.880

2.  Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits.

Authors:  J C Verd; C Peris; M Alegret; C Díaz; G Hernández; M Vázquez; T Adzet; J C Laguna; R M Sánchez
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

3.  The role of the LDL receptor in apolipoprotein B secretion.

Authors:  J Twisk; D L Gillian-Daniel; A Tebon; L Wang; P H Barrett; A D Attie
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 4.  Pathophysiology of dyslipidaemia in the metabolic syndrome.

Authors:  G D Kolovou; K K Anagnostopoulou; D V Cokkinos
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

5.  Serum and urine leptin concentration in children with nephrotic syndrome.

Authors:  Anna Wasilewska; Barbara Tomaszewska; Walentyna Zoch-Zwierz; Anna Biernacka; Krystyna Klewinowska; Alicja Koput
Journal:  Pediatr Nephrol       Date:  2005-03-22       Impact factor: 3.714

6.  Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.

Authors:  Thomas M van Himbergen; Seiko Otokozawa; Nirupa R Matthan; Ernst J Schaefer; Aaron Buchsbaum; Masumi Ai; Lambertus J H van Tits; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

7.  High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.

Authors:  Núria Roglans; Joan C Verd; Cristina Peris; Marta Alegret; Manuel Vázquez; Tomás Adzet; Cristina Díaz; Gonzalo Hernández; Juan C Laguna; Rosa M Sánchez
Journal:  Lipids       Date:  2002-05       Impact factor: 1.880

8.  Effect of weight loss, independent of change in diet composition, on apolipoprotein AI kinetic in men with metabolic syndrome.

Authors:  Caroline Richard; Patrick Couture; Sophie Desroches; Alice H Lichtenstein; Benoît Lamarche
Journal:  J Lipid Res       Date:  2012-11-02       Impact factor: 5.922

9.  Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.

Authors:  Dick C Chan; P Hugh R Barrett; Gerald F Watts
Journal:  Clin Biochem Rev       Date:  2004-02

10.  Regulation of plasma LDL: the apoB paradigm.

Authors:  Allan D Sniderman; Jacqueline De Graaf; Patrick Couture; Ken Williams; Robert S Kiss; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.